Compass Therapeutics Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential

Reuters

2025/06/05

Compass <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential

Compass Therapeutics Inc. has released a corporate presentation highlighting its recent developments and strategic initiatives. The presentation showcases the company's significant advancements in the field of antibody-based therapeutics, with a focus on the promising results of its Tovecimig (DLL4xVEGF-A) program for biliary tract cancer $(BTC.AU)$. Notably, the Phase 2/3 study achieved a 17.1% overall response rate in second-line BTC patients, compared to 5% with the standard FOLFOX treatment. The company is also progressing with a diversified pipeline, including several clinical candidates and a bispecific IND expected by Q4 2025. Compass Therapeutics reports a cash runway extending into Q1 2027, supported by a respected core investor base. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2541459850"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541459850\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541459850?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-05 14:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541459850","market":"nz","top_or_hot":-1,"title":"Compass Therapeutics Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compass Therapeutics Inc. has released a corporate presentation highlighting its recent developments and strategic initiatives. The presentation showcases the company's significant advancements in the field of antibody-based therapeutics, with a focus on the promising results of its Tovecimig (DLL4xVEGF-A) program for biliary tract cancer <a href=\"https://laohu8.com/S/BTC.AU\">$(BTC.AU)$</a>. Notably, the Phase 2/3 study achieved a 17.1% overall response rate in second-line BTC patients, compared to 5% with the standard FOLFOX treatment. The company is also progressing with a diversified pipeline, including several clinical candidates and a bispecific IND expected by Q4 2025. Compass Therapeutics reports a cash runway extending into Q1 2027, supported by a respected core investor base. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compass Therapeutics Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompass Therapeutics Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-05 14:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Compass Therapeutics Inc. has released a corporate presentation highlighting its recent developments and strategic initiatives. The presentation showcases the company's significant advancements in the field of antibody-based therapeutics, with a focus on the promising results of its Tovecimig (DLL4xVEGF-A) program for biliary tract cancer <a href=\"https://laohu8.com/S/BTC.AU\">$(BTC.AU)$</a>. Notably, the Phase 2/3 study achieved a 17.1% overall response rate in second-line BTC patients, compared to 5% with the standard FOLFOX treatment. The company is also progressing with a diversified pipeline, including several clinical candidates and a bispecific IND expected by Q4 2025. Compass Therapeutics reports a cash runway extending into Q1 2027, supported by a respected core investor base. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL7khrMs:1","article_id":"2541459850","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541459850","pubTimestamp":1749104924,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Compass Therapeutics Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CMPX":"Compass Therapeutics, Inc."},"translate_title":"Compass Therapeutics Inc.发布公司演示文稿，强调Tovecimig治疗胆道癌的2期数据和未来市场潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPX":0.9},"content_text":"Compass Therapeutics Inc. Unveils Corporate Presentation Highlighting Promising Phase 2 Data for Tovecimig in Biliary Tract Cancer and Future Market Potential\n    \n\n        Compass Therapeutics Inc. has released a corporate presentation highlighting its recent developments and strategic initiatives. The presentation showcases the company's significant advancements in the field of antibody-based therapeutics, with a focus on the promising results of its Tovecimig (DLL4xVEGF-A) program for biliary tract cancer $(BTC.AU)$. Notably, the Phase 2/3 study achieved a 17.1% overall response rate in second-line BTC patients, compared to 5% with the standard FOLFOX treatment. The company is also progressing with a diversified pipeline, including several clinical candidates and a bispecific IND expected by Q4 2025. Compass Therapeutics reports a cash runway extending into Q1 2027, supported by a respected core investor base. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Therapeutics Inc. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}